Page 5 - Sosei Heptares News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC

Tokyo, Japan and Cambridge, UK, 3 April 2024 - Nxera Pharma (“Nxera” or “the Company”; TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Japan pharmaceutical sector expert, Mr. Patrick Branch, as Head of Business Development for Japa.

Columbia universityNew yorkUnited statesUnited kingdomSoult ukpyolsiSouth koreaCity ofNxerapharma youtubeChris cargillNxera pharmaSosei heptaresPatrick branchMailman school of public health new yorkMasters of public healthUniversity of londonUniversity of nottingham

Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma

Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomSoult ukpyolsiSouth koreaCity ofKazuhiko yoshizumiFrazer hallCandelle chongKieran johnsonKuniaki kagaDavid roblinNxera pharmaMaya bennisonKeiko tomitaTomohiro tohyamaToshihiro maedaMatt barnes

Sosei Heptares Confirms Re-election of its Board and

Sosei Heptares Confirms Re-election of its Board and
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomSoult ukpyolsiSouth koreaChris cargillTomohiro tohyamaShinichi tamuraErica hollingsworthMaya bennisonSatoshi tanakaMiwa sekiToshihiro maedaNxera pharmaKazuhiko yoshizumiRolf soderstromKeiko tomita

Head to Head Review: Takeda Pharmaceutical (NYSE:TAK) vs Nurix Therapeutics (NASDAQ:NRIX)

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Volatility and Risk Takeda Pharmaceutical has a beta […]

United statesSan franciscoXenetic biosciencesLeuplin enantoneSosei heptaresSelecta biosciencesHeidelberg pharmaFalk pharma gmbTakecab vocintiAdynovate adynoviSelecta bioscienceFalk pharmaHemofil immunate immunineGattex revestivePantoloc controlocGenevant sciences corporation

Boehringer Ingelheim and Sosei Heptares target schizophrenia treatments

Sosei Heptares and Boehringer Ingelheim have joined forces for a renewed assault on schizophrenia. Sosei Heptares, which has major R & D operations in Cambridge, will receive an upfront payment of €25 million from its German partner on signing and is eligible for handsome on-payments.

United kingdomSosei heptaresBoehringer ingelheim